Neos Therapeutics Inc (NEOS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Neos Therapeutics Inc (NEOS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9833
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neos Therapeutics Inc (Neos Therapeutics), formerly Neostx Inc, develops, manufactures, and commercializes branded pharmaceuticals. The company’s portfolio includes Adzenys XR-ODT that is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients of six years age and older; and Tussionex that is indicated for cough and upper respiratory symptoms of cold. Its pipeline encompasses investigational candidates for the treatment of ADHD. Neos Therapeutics’ products are orally disintegrating tablets (ODT) or liquid suspension dosage forms, which are based on its proprietary extended-release (XR) drug delivery technology platform. The company also manufactures and markets its generic equivalent of the branded product Tussionex. Neos Therapeutics is headquartered in Grand Prairi, Texas, the US.

Neos Therapeutics Inc (NEOS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 10
Venture Financing 11
Neos Therapeutics Raises USD20.6 Million in Venture Financing 11
Neos Therapeutics Raises USD8 Million in Venture Financing 12
Neos Therapeutics Raises US$2.5 Million In Venture Financing 13
Neos Therapeutics Raises US$7.4 Million In Series C Financing 14
Neos Therapeutics Raises US$8 Million In Venture Financing 15
Neos Therapeutics Raises US$18.3 Million In Venture Financing 16
Licensing Agreements 17
Neos Therapeutics Enters into Licensing Agreement with NeuRx Pharma 17
Neos Therapeutics Enters into Licensing Agreement with Shire 18
Equity Offering 19
Neos Therapeutics Prices Public Offering of Shares for USD40 Million 19
Neos Therapeutics Raises USD30 million in Public Offering of Shares 21
Neos Therapeutics Raises USD25 million in Public Offering of Shares 22
Neos Therapeutics Files Registration Statement for Public Offering of Shares for USD69 Million 24
Neos Therapeutics Raises USD82.8 Million in IPO 25
Neos Therapeutics Inc – Key Competitors 27
Neos Therapeutics Inc – Key Employees 28
Neos Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 08, 2018: Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results 30
Aug 08, 2018: Neos Therapeutics Reports Second Quarter 2018 Financial Results 31
May 09, 2018: Neos Therapeutics Reports First Quarter 2018 Financial Results 32
Mar 15, 2018: Neos Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results 34
Aug 08, 2017: Neos Therapeutics Reports Second Quarter 2017 Financial Results 36
May 09, 2017: Neos Therapeutics Reports First Quarter 2017 Financial Results 37
Mar 14, 2017: Neos Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results 38
Corporate Communications 40
Jun 27, 2018: Neos Therapeutics Names Jerry McLaughlin As Chief Executive Officer 40
Other Significant Developments 41
Feb 20, 2018: Neos Therapeutics Reiterates Confidence in Strategic Plan and Value Creation Opportunities 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neos Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neos Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 10
Neos Therapeutics Raises USD20.6 Million in Venture Financing 11
Neos Therapeutics Raises USD8 Million in Venture Financing 12
Neos Therapeutics Raises US$2.5 Million In Venture Financing 13
Neos Therapeutics Raises US$7.4 Million In Series C Financing 14
Neos Therapeutics Raises US$8 Million In Venture Financing 15
Neos Therapeutics Raises US$18.3 Million In Venture Financing 16
Neos Therapeutics Enters into Licensing Agreement with NeuRx Pharma 17
Neos Therapeutics Enters into Licensing Agreement with Shire 18
Neos Therapeutics Prices Public Offering of Shares for USD40 Million 19
Neos Therapeutics Raises USD30 million in Public Offering of Shares 21
Neos Therapeutics Raises USD25 million in Public Offering of Shares 22
Neos Therapeutics Files Registration Statement for Public Offering of Shares for USD69 Million 24
Neos Therapeutics Raises USD82.8 Million in IPO 25
Neos Therapeutics Inc, Key Competitors 27
Neos Therapeutics Inc, Key Employees 28

List of Figures
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neos Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Neos Therapeutics Inc (NEOS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Steris Plc (STE):製薬・医療:M&Aディール及び事業提携情報
    Summary Steris Plc (Steris), formerly Steris Ltd is a medical equipment company that provides infection prevention and other procedural products. The company offers products such as OR integration systems, sterilizers, surgical tables and lights, perioperative solutions, endoscopy accessories and ba …
  • Hutchison 3G UK Limited:戦略・SWOT・企業財務分析
    Hutchison 3G UK Limited - Strategy, SWOT and Corporate Finance Report Summary Hutchison 3G UK Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • GW Pharmaceuticals Plc (GWP)-製薬・医療分野:企業M&A・提携分析
    Summary GW Pharmaceuticals plc (GW Pharmaceuticals) is a biopharmaceutical company which discovers, develops and commercializes innovative therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, f …
  • The Miyazaki Bank Ltd.:企業の戦略・SWOT・財務情報
    The Miyazaki Bank Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Miyazaki Bank Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Driver and Vehicle Standards Agency:企業の戦略的SWOT分析
    Driver and Vehicle Standards Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Werner Enterprises, Inc.:企業の戦略・SWOT・財務情報
    Werner Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Werner Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • C&C Group plc:戦略・SWOT・企業財務分析
    C&C Group plc - Strategy, SWOT and Corporate Finance Report Summary C&C Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Oberoi Realty Limited:企業の戦略・SWOT・財務情報
    Oberoi Realty Limited - Strategy, SWOT and Corporate Finance Report Summary Oberoi Realty Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • DTE Energy Co (DTE):企業の財務・戦略的SWOT分析
    DTE Energy Co (DTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Companhia Energetica de Sao Paulo (CESP6)-エネルギー分野:企業M&A・提携分析
    Summary Companhia Energetica de Sao Paulo (CESP) is a state-owned integrated electric utility. It plans, constructs, and operates electric energy generation and commercialization systems. The company generates energy from hydro source. CESP owns power plants at at Rio Paran, Rio Paraibuna, and Rio J …
  • Genfit SA (GNFT):企業の財務・戦略的SWOT分析
    Summary Genfit SA (Genfit) is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include GFT505, biomarkers, TGFTX1 and TGFTX4. Its TGFTX1 is a research program …
  • Amyris Inc (AMRS):企業の財務・戦略的SWOT分析
    Summary Amyris Inc (Amyris) formerly Amyris Biotechnologies Inc, is a healthcare product manufacturer that offers integrated renewable products. The company provides alternatives to a range of petroleum-sourced products and rare materials. It offers health and wellness products, clean beauty product …
  • Manali Petrochemicals Ltd (MANALIPETC):企業の財務・戦略的SWOT分析
    Summary Manali Petrochemicals Ltd (MPL), a subsidiary of Southern Petrochemical Industries Corp Ltd, is a chemical company that develops and markets petrochemical products. The company offers products such as propylene oxide, propylene glycol, flexible and molded polyols, rigid polyols and elastomer …
  • Caspian Energy Inc. (CKZ.H)-石油・ガス分野:企業M&A・提携分析
    Summary Caspian Energy Inc. (Caspian) is an independent upstream oil and gas company that explores for and develops hydrocarbon reserves, and produces oil and gas. Caspian and its subsidiaries hold interests in Aral Petroleum Capital LLP, which holds an exclusive license which entitles it to explore …
  • GridEdge Networks Inc.:企業の戦略的SWOT分析
    GridEdge Networks Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Citrix Systems Inc (CTXS):企業の財務・戦略的SWOT分析
    Citrix Systems Inc (CTXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Quadrise Fuels International Plc (QFI):企業の財務・戦略的SWOT分析
    Quadrise Fuels International Plc (QFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Zoologischer Garten Berlin AG:企業の戦略・SWOT・財務情報
    Zoologischer Garten Berlin AG - Strategy, SWOT and Corporate Finance Report Summary Zoologischer Garten Berlin AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Advantest Corporation (6857):企業の財務・戦略的SWOT分析
    Advantest Corporation (6857) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Synedgen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Synedgen Inc (Synedgen) is a biotechnology company that focuses on the discovery and development of polysaccharide-based drugs. The company’s pipeline products include SYGN 113; SYGN 115; SYGN 146; SYGN 303; SYGN 313 and SYGN 399 among others. Synedgen develops products for the treatment of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆